EPS for Becton, Dickinson and Company (BDX) Expected At $2.84

July 11, 2018 - By Ash

Becton, Dickinson and Company (NYSE:BDX) LogoInvestors sentiment decreased to 1.05 in 2018 Q1. Its down 0.50, from 1.55 in 2017Q4. It is negative, as 69 investors sold Becton, Dickinson and Company shares while 375 reduced holdings. 114 funds opened positions while 350 raised stakes. 219.77 million shares or 1.86% more from 215.77 million shares in 2017Q4 were reported.
Scholtz Ltd Company holds 2.01% in Becton, Dickinson and Company (NYSE:BDX) or 12,535 shares. Parkside Bancorporation & Tru owns 0.06% invested in Becton, Dickinson and Company (NYSE:BDX) for 712 shares. Price T Rowe Assocs Incorporated Md reported 35.81 million shares. Nippon Life Americas has invested 0.86% in Becton, Dickinson and Company (NYSE:BDX). Canal Co holds 13,123 shares or 1% of its portfolio. Harvey Investment Limited Liability stated it has 0.24% in Becton, Dickinson and Company (NYSE:BDX). Vanguard Group holds 0.2% or 21.10M shares. Ally Financial, Michigan-based fund reported 5,000 shares. Citigroup Inc has invested 0.01% of its portfolio in Becton, Dickinson and Company (NYSE:BDX). Tompkins Corp stated it has 473 shares or 0.02% of all its holdings. Cibc Ww Markets reported 0.03% stake. Howland Cap Limited holds 0.09% or 5,138 shares in its portfolio. Morgan Stanley holds 0.1% of its portfolio in Becton, Dickinson and Company (NYSE:BDX) for 1.64 million shares. Invesco has invested 0.1% of its portfolio in Becton, Dickinson and Company (NYSE:BDX). Vident Invest Advisory Limited Company reported 2,997 shares.

Since February 23, 2018, it had 1 buy, and 6 insider sales for $9.39 million activity. Another trade for 176 shares valued at $38,416 was made by RING TIMOTHY M on Friday, February 23. Borzi James W sold 4,048 shares worth $910,726. Gallagher John E also sold $1.21M worth of Becton, Dickinson and Company (NYSE:BDX) shares. Shabshab Nabil sold 10,209 shares worth $2.31M. Conroy Alexandre sold $4.60 million worth of Becton, Dickinson and Company (NYSE:BDX) on Monday, May 21. Another trade for 500 shares valued at $112,535 was made by Melcher David F on Monday, May 7.

Analysts expect Becton, Dickinson and Company (NYSE:BDX) to report $2.84 EPS on August, 2.They anticipate $0.38 EPS change or 15.45 % from last quarter’s $2.46 EPS. BDX’s profit would be $758.86M giving it 21.53 P/E if the $2.84 EPS is correct. After having $2.65 EPS previously, Becton, Dickinson and Company’s analysts see 7.17 % EPS growth. The stock increased 0.03% or $0.08 during the last trading session, reaching $244.63. About 967,297 shares traded. Becton, Dickinson and Company (NYSE:BDX) has risen 19.79% since July 12, 2017 and is uptrending. It has outperformed by 7.22% the S&P500.

Becton, Dickinson and Company (NYSE:BDX) Ratings Coverage

Among 9 analysts covering Becton Dickinson (NYSE:BDX), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Becton Dickinson had 9 analyst reports since January 19, 2018 according to SRatingsIntel. The stock of Becton, Dickinson and Company (NYSE:BDX) has “Hold” rating given on Thursday, February 8 by RBC Capital Markets. J.P. Morgan upgraded the shares of BDX in report on Thursday, June 21 to “Buy” rating. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, February 7. Piper Jaffray maintained Becton, Dickinson and Company (NYSE:BDX) rating on Tuesday, February 6. Piper Jaffray has “Buy” rating and $260.0 target. Jefferies maintained Becton, Dickinson and Company (NYSE:BDX) rating on Tuesday, February 6. Jefferies has “Buy” rating and $260.0 target. The firm has “Buy” rating given on Tuesday, April 10 by Citigroup. The stock of Becton, Dickinson and Company (NYSE:BDX) earned “Overweight” rating by JP Morgan on Thursday, June 21.

Becton, Dickinson and Company develops, makes, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company has market cap of $65.37 billion. It operates in two divisions, BD Medical and BD Life Sciences. It currently has negative earnings. The BD Medical segment offers syringes, pen needles, and IV sets for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; and prefillable drug delivery systems.

More notable recent Becton, Dickinson and Company (NYSE:BDX) news were published by: Streetinsider.com which released: “Becton Dickinson (BDX) Acquires TVA Medical” on July 09, 2018, also Bizjournals.com with their article: “Tempe lands first tenant for IDEA development” published on July 11, 2018, Schaeffersresearch.com published: “2 Medical Technology Stocks Named Top Picks by JP Morgan Analyst” on June 21, 2018. More interesting news about Becton, Dickinson and Company (NYSE:BDX) were released by: Benzinga.com and their article: “Becton Dickinson Positioned For Top-, Bottom-Line Outperformance, JPMorgan Says In Upgrade” published on June 21, 2018 as well as Bizjournals.com‘s news article titled: “New San Antonio incentive database shows strong returns” with publication date: July 11, 2018.

Becton, Dickinson and Company (NYSE:BDX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.